NASDAQ:IMMU - Immunomedics, Inc.
$16.99
 $0.34
+2.04%
4:00PM EDT
2019-04-18
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  IMMU     avg for
industry  
  avg for
sector  
42 stocks weight:  310. 06   203. 85   241. 91  
42 stocks rank:  583. 00   1. 44 K 1. 05 K
# analyst opinions:  9. 00   14. 51   13. 97  
mean recommendation:  2. 00   2. 09   2. 01  

quick ratio:  15. 69   5. 27   1. 81  
current ratio:  15. 90   5. 62   2. 25  

target price low:  17. 00   84. 80   115. 21  
target price avg:  25. 11   111. 51   137. 51  
target price high:  40. 00   135. 81   157. 84  
1-yr high:  26. 76   114. 23   138. 78  
last close:  16. 99   87. 66   116. 69  
50-day avg:  16. 88   95. 54   123. 44  
200-day avg:  19. 76   94. 25   121. 11  
1-yr low:  13. 12   72. 78   98. 34  
volume:  2. 90 M 4. 11 M 8. 07 M
50-day avg volume:  2. 43 M 2. 76 M 5. 02 M
200-day avg volume:  2. 39 M 2. 92 M 4. 59 M

1-day return:  2. 04 % -0. 41 % 0. 07 %
this week return:  -8. 21 % -5. 74 % -4. 11 %
12-wk return:  16. 93 % 1. 61 % -0. 05 %
52-wk return:  3. 16 % 3. 12 % 8. 78 %

enterprise value (EV):  2. 67 B 48. 94 B 114. 64 B
market cap:  3. 24 B 43. 07 B 104. 73 B
EBITDA:  -284. 87 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -9. 39   4. 22   12. 73  
total debt:  19. 80 M 12. 24 B 16. 73 B
debt/equity:  5. 83   46. 71   89. 62  
net income (common):  -315. 34 M 2. 20 B 4. 20 B

shares outstanding:  190. 96 M 571. 70 M 1. 24 B
shares:  152. 41 M 571. 81 M 1. 23 B
shares short:  34. 74 M 10. 17 M 13. 00 M
shares short prior month:  29. 75 M 9. 54 M 17. 33 M
short ratio:  14. 62   5. 41   3. 28  
short % of float:  20. 55 % 5. 45 % 2. 38 %
total cash/share:  3. 07   11. 14   9. 33  
total cash:  585. 53 M 6. 71 B 7. 15 B
operating cash flow:  -261. 33 M 4. 15 B 4. 30 B

book value:  1. 40   12. 78   26. 92  
price/book:  12. 13   3. 06   -1. 74  
gross profits:  -187. 77 M 8. 04 B 34. 86 B
operating margins:  0. 00 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  0. 00 % 37. 08 % 55. 70 %

1-yr max volatility:  -26. 42 % --- ---
1-yr mean volatility:  0. 09 % 0. 03 % 0. 04 %

1-yr EPS:  -1. 67   2. 40   4. 10  
forward EPS:  -1. 63   3. 97   7. 13  
P/E:  -10. 16   13. 63   22. 72  
forward P/E:  -10. 42   -15. 95   13. 99  
PE/G:  1. 40   -1. 65   -1. 32  
growth:  -7. 28 % 127. 12 % 29. 61 %
earnings high:  -0. 30   1. 00   1. 66  
earnings avg:  -0. 36   0. 77   1. 53  
earnings low:  -0. 45   0. 50   1. 39  
revenue high:  6. 30 M 2. 68 B 10. 78 B
revenue avg:  1. 10 M 2. 59 B 10. 57 B
revenue low:  -0. 00   2. 49 B 10. 36 B

beta (1yr vs S&P500):  1. 50   1. 25   0. 93  
sharpe (1yr):  0. 38   0. 37   0. 70  

held % insiders:  7. 19 % 6. 39 % 3. 38 %
held % institutions:  84. 82 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : IMMU
.     + 2.45 =          2.45 :: INITIAL WEIGHT
.   + 71.639 =        74.089 :: inverse volume-to-price addition
.   + 35.248 =       109.337 :: spline projection addition
.    x 3.675 =        401.81 :: 13 weeks' performance factor
.    x 1.017 =       408.788 :: one-year gains+dividend factor
.    x 1.431 =       585.148 :: industry recommendation factor
.     x 2.22 =      1298.877 :: symbol recommendation factor
.    x 2.828 =       3672.91 :: current ratio factor
.    x 1.033 =      3795.842 :: quick ratio factor
.    x 1.034 =      3923.511 :: short ratio factor
.    x 2.245 =       8810.09 :: price-to-book factor
.    x 1.061 =      9344.126 :: debt-to-equity factor
.    x 1.042 =      9732.957 :: 5-day avg > 50-day avg
.    x 1.976 =     19230.462 :: P/E weight
.     x 0.92 =     17693.756 :: PE/G factor
.    x 1.481 =     26208.912 :: beta factor
.    x 0.375 =      9832.905 :: sharpe factor
.    x 1.023 =     10061.964 :: target low factor
.     x 1.23 =     12380.655 :: target mean factor
.    x 1.116 =      13821.46 :: target high factor
.     x 1.31 =     18104.563 :: industry 2-weeks return factor
.    x 0.935 =     16922.931 :: "drift" penalty 3 days ago
.    x 0.929 =     15728.146 :: "drift" penalty 4 days ago
.     x 0.98 =     15417.903 :: overall "drift" factor
.    x 0.999 =     15400.999 :: largest single-day jump factor
.     x 1.01 =     15554.864 :: mean volatility factor
.    x 1.098 =     17073.964 :: 42-day mean volatility factor
.      x 1.0 =     17071.192 :: factor hist industry gain for week 16
.   cubeRoot =        25.749 :: reduced to standardize
.  + 284.307 =       310.056 :: add/subtract for performance
.                    310.056 :: FINAL WEIGHT for NASDAQ:IMMU


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org